Two months after an open letter warned of potential safety problems, mounting concern has surrounded Vykat XR, a medication marketed by Neurocrine Biosciences for Prader‑Willi syndrome. The drug, which received approval 18 months ago to treat the rare genetic disorder, has been tied in case reports to seven deaths and nearly 100 hospitalizations since it reached the market.
A former FDA regulator, Karen Vogt, has urged the FDA to withdraw Vykat XR from use because of those safety signals. Patient advocates and some clinicians have echoed growing alarm, while other experts cautioned against drawing firm causal conclusions from the available reports.
STAT obtained case reports submitted to regulators via the Freedom of Information Act. Those records document the seven deaths and the nearly 100 hospitalizations that have been associated with patients taking Vykat XR since the drug’s approval 18 months ago. The reports describe complex clinical situations that frequently involve additional medical conditions and concurrent medications.
The STAT story emphasizes that case reports alone do not prove causation. The reports reflect events reported after treatment with Vykat XR, but many of the individual records describe patients with multiple health problems and other therapies that could have contributed to the outcomes.
Not all observers interpret the available information the same way. Some experts cited in the STAT reporting said the pattern of reports is sufficient to conclude the therapy is causing unacceptable harm. Others urged caution, noting the limitations of spontaneous and post-approval case reports for establishing direct cause-and-effect relationships.
Karen Vogt, identified in the reporting as a pediatric endocrinologist and former FDA medical officer, has publicly called for withdrawal of the drug from the market. Patient advocacy groups have also expressed heightened concern since the open letter’s release two months earlier.
Prader‑Willi syndrome is a rare genetic condition that can cause a range of developmental and medical challenges; the public portion of the STAT piece describes the disorder as one that can produce an insatiable feeling of hunger. Vykat XR was approved as a treatment for people with this syndrome roughly 18 months before the STAT report was published on Oct. 13, 2026.
The STAT reporting does not include clinical trial data, prescribing details, or Neurocrine’s response within the publicly available excerpt. It does make clear that safety-related case reports have accumulated in the post-approval period and that the data obtained through FOIA were submitted to regulators.
The STAT article stresses the limitations of case reports: they can signal potential problems but are often incomplete and do not by themselves prove that a drug caused an adverse outcome. Many of the reported cases involved patients with complex medical backgrounds and multiple concomitant medications, complicating attempts to determine the root cause of an individual death or hospitalization.
The version of the STAT article accessible without a STAT+ subscription provides these core findings and context but indicates that more detailed reporting and analysis were published as part of a STAT+ subscriber-exclusive story. As presented in the public excerpt, specific details about individual cases, timelines, Neurocrine Biosciences’ responses, and any FDA actions or reviews beyond the call for withdrawal by a former regulator were not reported in the publicly available portion of the source.
Post‑approval safety signals can affect prescribing decisions, regulatory oversight, and patient monitoring. The reports tied to Vykat XR — seven deaths and nearly 100 hospitalizations — have prompted some clinicians and advocates to reassess the balance of benefits and risks for people with Prader‑Willi syndrome. Calls for the FDA to act, including requests to withdraw the drug, reflect concern that the current safety evidence warrants regulatory intervention.
At the same time, experts who caution against assuming causation point to the need for careful review of the data, including clinical detail, patient histories, and any available systematic analyses that could clarify whether the medication itself is responsible for the adverse events.
The STAT story documents growing alarm and notes the presence of case reports obtained by FOIA. It also reports calls from a former FDA official for withdrawal and differing expert opinions about whether the evidence proves harm. The article does not report subsequent regulatory steps by the FDA or a published, wide-ranging epidemiologic analysis establishing causality.
Further public reporting, regulatory statements, or company responses would be needed to clarify whether regulators will change the drug’s approval status, add new warnings, require additional studies, or take other actions. The STAT piece indicates that more in‑depth coverage appeared behind a STAT+ paywall; those subscriber-only sections may include additional details not available in the public excerpt.
This article is based solely on the publicly available portion of the STAT report published Oct. 13, 2026, by Adam Feuerstein. Where the public report did not provide further specifics — including detailed case timelines, Neurocrine’s comments in response to the FOIA records, or any ongoing FDA review actions — those details were not reported in the source material available to this rewrite.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.